SpringWorks Therapeutics, Inc.
- Jurisdiction
United States - ISIN
US85205L1070 (SWTX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Read full profile
Fundamentals
- Net revenue
€187.37M - Gross margin
93.2% - EBIT
-€225.81M - EBIT margin
-120.5% - Net income
-€216.59M - Net margin
-115.6%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Josh Gottheimer | August 11, 2025 | $1.00K–$15.00K |
| Gilbert Cisneros | July 10, 2025 | $15.00K–$50.00K |
| Gilbert Cisneros | February 11, 2025 | $1.00K–$15.00K |
| Josh Gottheimer | August 15, 2024 | $1.00K–$15.00K |
| Josh Gottheimer | July 9, 2024 | $1.00K–$15.00K |
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Stanley Druckenmiller |
|
|
|
Sell |
| George Soros |
|
|
|
Sell |
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 5, 2024 (Q1 2024)